BridGene Biosciences

Curated by Signal

Developer of small-molecule drugs for the treatment of cancer

Overview

Developer of small-molecule drugs for the treatment of cancer. The company utilizes its proprietary Chemoproteomics platform, IMTAC that enables the screening of small molecules against all the proteins in live cells to discover drug candidates for high value and hard-to-drug targets that cause diseases.

Key facts

Founded: 2018
Headquarters: Sunnyvale, United States
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

5 products and services: Sign up to view

Contact

Primary office: Sign up to view
Email: Sign up to view
Phone: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

NanoVibronix
Provider of ultrasound therapy devices for multiple health purposes
Life Sciences TechnologyElmsford, United States
ProLon Fasting Mimicking Diet
Provider of dietary programs for metabolic health
Life Sciences TechnologyLos Angeles, United States
Bactana Corporation
Developer of proprietary microbiome technology
Life Sciences TechnologyFarmington, United States

About BridGene Biosciences

What does BridGene Biosciences do?

Developer of small-molecule drugs for the treatment of cancer.

Where is BridGene Biosciences headquartered?

BridGene Biosciences is headquartered in Sunnyvale, United States.

When was BridGene Biosciences founded?

BridGene Biosciences was founded in 2018.

Which sector is BridGene Biosciences in?

BridGene Biosciences operates in Life Sciences Technology.

Who are BridGene Biosciences's competitors?

Companies similar to BridGene Biosciences include NanoVibronix, ProLon Fasting Mimicking Diet, and Bactana Corporation.